Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases

被引：0

作者：

Lin, Pei ^{[1
]}

Zhang, Dandan ^{[1
]}

Lin, Jun ^{[1
]}

机构：

[1] Jiangnan Univ, Sch Life Sci & Hlth Engn, Wuxi 214122, Peoples R China

来源：

CURRENT TOPICS IN MEDICINAL CHEMISTRY | 2023年 / 23卷 / 28期

关键词：

Bruton's tyrosine kinase; Autoimmune disease; B cell receptor; Inhibitors; Rheumatoid arthritis; Multiple sclerosis; Systemic lupus erythematosus; BRUTONS TYROSINE KINASE; X-LINKED AGAMMAGLOBULINEMIA; PIRTOBRUTINIB; TOXICITIES; ACTIVATION; MECHANISMS; EFFICACY;

D O I：

10.2174/0115680266264515230921052521

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Bruton tyrosine kinase (BTK) is an important protein of the tyrosine kinase family and plays a key role in signal transduction, proliferation, migration, and survival in B lymphocytes. The inhibition of BTK is a promising therapy for various autoimmune diseases (AD) involving abnormal B cell function, such as rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus (SLE). This article briefly summarizes the role of BTK in the BCR signaling pathway, the development process of BTK inhibitors, and especially the latest progress of their clinical trials for the treatment of AD.

引用

页码：2609 / 2620

页数：12

共 83 条

[1] Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor [J].

Adasme, Melissa F. ;

Parisi, Daniele ;

Van Belle, Kristien ;

Salentin, Sebastian ;

Haupt, V. Joachim ;

Jennings, Gary S. ;

Heinrich, Joerg-Christian ;

Herman, Jean ;

Sprangers, Ben ;

Louat, Thierry ;

Moreau, Yves ;

Schroeder, Michael .

PLOS ONE, 2020, 15 (05)

[2]

ALLEN RC, 1994, AM J HUM GENET, V54, P25

[3] Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase [J].

Angst, Daniela ;

Gessier, Francois ;

Janser, Philipp ;

Vulpetti, Anna ;

Walchli, Rudolf ;

Beerli, Christian ;

Littlewood-Evans, Amanda ;

Dawson, Janet ;

Nuesslein-Hildesheim, Barbara ;

Wieczorek, Grazyna ;

Gutmann, Sascha ;

Scheufler, Clemens ;

Hinniger, Alexandra ;

Zimmerlin, Alfred ;

Funhoff, Enrico G. ;

Pulz, Robert ;

Cenni, Bruno .

JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (10) :5102-5118

[4] Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib [J].

Awan, Farrukh T. ;

Schuh, Anna ;

Brown, Jennifer R. ;

Furman, Richard R. ;

Pagel, John M. ;

Hillmen, Peter ;

Stephens, Deborah M. ;

Woyach, Jennifer ;

Bibikova, Elena ;

Charuworn, Prista ;

Frigault, Melanie M. ;

Hamdy, Ahmed ;

Izumi, Raquel ;

Linghu, Bolan ;

Patel, Priti ;

Wang, Min Hui ;

Byrd, John C. .

BLOOD ADVANCES, 2019, 3 (09) :1553-1562

[5] The immune system as a social network [J].

Bergthaler, Andreas ;

Menche, Joerg .

NATURE IMMUNOLOGY, 2017, 18 (05) :481-482

[6] Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia [J].

Brown, J. R. ;

Eichhorst, B. ;

Hillmen, P. ;

Jurczak, W. ;

Kazmierczak, M. ;

Lamanna, N. ;

O'Brien, S. M. ;

Tam, C. S. ;

Qiu, L. ;

Zhou, K. ;

Simkovic, M. ;

Mayer, J. ;

Gillespie-Twardy, A. ;

Ferrajoli, A. ;

Ganly, P. S. ;

Weinkove, R. ;

Grosicki, S. ;

Mital, A. ;

Robak, T. ;

Osterborg, A. ;

Yimer, H. A. ;

Salmi, T. ;

Wang, M. -D. -Y. ;

Fu, L. ;

Li, J. ;

Wu, K. ;

Cohen, A. ;

Shadman, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (04) :319-332

[7] Bruton Tyrosine Kinase Inhibitors Present and Future [J].

Burger, Jan A. .

CANCER JOURNAL, 2019, 25 (06) :386-393

[8] Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial [J].

Byrd, John C. ;

Hillmen, Peter ;

Ghia, Paolo ;

Kater, Arnon P. ;

Chanan-Khan, Asher ;

Furman, Richard R. ;

O'Brien, Susan ;

Yenerel, Mustafa Nuri ;

Illes, Arpad ;

Kay, Neil ;

Garcia-Marco, Jose A. ;

Mato, Anthony ;

Pinilla-Ibarz, Javier ;

Seymour, John F. ;

Lepretre, Stephane ;

Stilgenbauer, Stephan ;

Robak, Tadeusz ;

Rothbaum, Wayne ;

Izumi, Raquel ;

Hamdy, Ahmed ;

Patel, Priti ;

Higgins, Kara ;

Sohoni, Sophia ;

Jurczak, Wojciech .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) :3441-+

[9] Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases [J].

Caldwell, Richard D. ;

Qiu, Hui ;

Askew, Ben C. ;

Bender, Andrew T. ;

Brugger, Nadia ;

Camps, Montserrat ;

Dhanabal, Mohanraj ;

Dutt, Vikram ;

Eichhorn, Thomas ;

Gardberg, Anna S. ;

Goutopoulos, Andreas ;

Grenningloh, Roland ;

Head, Jared ;

Healey, Brian ;

Hodous, Brian L. ;

Huck, Bayard R. ;

Johnson, Theresa L. ;

Jones, Christopher ;

Jones, Reinaldo C. ;

Mochalkin, Igor ;

Morandi, Federica ;

Ngan Nguyen ;

Meyring, Michael ;

Potnick, Justin R. ;

Santos, Dusica Cvetinovic ;

Schmidt, Ralf ;

Sherer, Brian ;

Shutes, Adam ;

Urbahns, Klaus ;

Follis, Ariele Viacava ;

Wegener, Ansgar A. ;

Zimmerli, Simone C. ;

Liu-Bujalski, Lesley .

JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (17) :7643-7655

[10] Obinutuzumab: First Global Approval [J].

Cameron, Fiona ;

McCormack, Paul L. .

DRUGS, 2014, 74 (01) :147-154

← 1 2 3 4 5 6 7 8 9 →